Loading…
Loading…
HUMDF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for HUMDF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for HUMDF and 80,000+ other tickers.
See exactly how HUMDF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for HUMDF and 80,000+ other tickers.
Hua Medicine (Shanghai) Ltd. is a clinical-stage pharmaceutical firm specializing in treatments for diabetes, primarily targeting the Chinese market. Its flagship product is Dorzagliatin (also known as HMS5552), an oral medication currently being developed for managing Type 2 Diabetes (T2D). Additionally, the company is advancing Dorzagliatin through Phase I clinical trials when combined with Metformin, Sitagliptin, and Empagliflozin, also for T2D therapy. Dorzagliatin's potential extends to other applications, including combinations with Pioglitazone for NASH, with GLP-1 for Alzheimer's…
